Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement

1

ALK-positive anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma with poor outcomes in cases involving the central nervous system (CNS).
2

Alectinib, an ALK inhibitor, shows promise in treating ALK-positive ALCL with CNS involvement, as demonstrated in two clinical cases.
3

The first case involved an 18-year-old male who achieved long-term remission after alectinib treatment combined with CNS-directed chemotherapy.
4

The second case featured a 31-year-old female with primary isolated CNS ALCL, who also achieved complete remission with alectinib and CNS-directed chemotherapy.
5

These cases suggest that alectinib may be an effective treatment option for both relapsed and primary CNS ALK-positive ALCL.

Frontiers In Oncology

by Milda Mikalonytė, Vilhelmas Landsbergis, Lukas Kevličius, Skirmantė Černauskienė, Linas Davainis, Andrius Žučenka, Igoris Trociukas, Regina Pileckytė, Birutė Davainienė, Inga Šlepikienė, Gintarė Ražanskienė, Ugnius Mickys, Jonas Ražanskas, Jūratė Dementavičienė, Mindaugas Stoškus, Raminta Batiuškaitė, Laimonas Griškevičius
June 9, 2026

1